Sygnis Pharma

TGR BioSciences Pty Ltd, based in Adelaide, Australia, is a private company founded in 2001 that specializes in innovative solutions for cell-based research applications. With a team of experts in cell biology, biochemistry, and immunoassay design, TGR BioSciences develops high-quality products and services that support drug discovery efforts globally. The company has created a patented antibody immobilization system that enhances assay speed, simplicity, and performance, thereby enabling medical developers to create advanced treatments for complex diseases. TGR BioSciences is dedicated to providing technical support and superior performance in its offerings, contributing to the advancement of research and therapeutic development in the biomedical field.

Innova Biosciences Ltd. is a manufacturer based in Cambridge, United Kingdom, specializing in the development of antibody labeling and bioconjugation kits for the life science sector. The company offers a diverse range of products, including enzyme and fluorescent protein labeling kits, rapid labeling kits, antibody purification kits, and gold conjugation kits, among others. Its innovative products are utilized in various applications, including hospital and pharmaceutical research labs, immunodiagnostics, and consumer items like pregnancy tests. Innova Biosciences operates through a global distributor network and direct sales, ensuring broad accessibility of its offerings. Founded in 2002, the company has established itself as a key player in the field of labeling reagents and bioconjugation technologies.

Expedeon Ltd. specializes in developing and marketing innovative solutions for protein-based research and production, catering to the needs of protein researchers across various applications. Established in 2003 and based in Harston, United Kingdom, the company offers a range of products, including InstantBlue, a ready-to-use protein gel stain, and BradfordUltra, which detects total protein in challenging environments. Its portfolio encompasses polyacrylamide gel electrophoresis equipment, protein protection and refolding kits, purification resins, and enzymes. Expedeon also provides custom services and off-the-shelf products, supporting workflows in life sciences and diagnostics, such as liquid biopsy and immunoassay development. Known for its commitment to quality, all products undergo stringent quality control testing to ensure reliability and ease of use, ultimately saving researchers time and costs. Expedeon operates as a subsidiary of Abcam plc and is fully owned by SYGNIS AG, with laboratory and commercial facilities located in the UK, USA, Singapore, Germany, and Spain, allowing for rapid global delivery of products.

C.B.S. Scientific Co. is a manufacturer of electrophoresis equipment and scientific instruments used in life science research, with a global brand presence in genomics and proteomics applications. The company offers a broad range of electrophoresis systems, including horizontal and vertical options, as well as DNA mutation detection systems and DNA workstations designed to support contaminant-free DNA amplification workflows. Its products are engineered for versatility, high performance, and ease of use, enabling researchers to perform established applications and adapt to evolving methodologies. By supplying complementary instrumentation that integrates with broader life science research workflows, C.B.S. Scientific Co. serves laboratories worldwide seeking reliable, adaptable tools for genomics and proteomics experiments.

Amnestix, Inc. is a biopharmaceutical company based in Burlingame, California, founded in 2006. It specializes in the development of novel therapeutics aimed at enhancing cognitive function, particularly in relation to memory disorders. The company concentrates on creating small-molecule compounds for the treatment of various neurological conditions, including Alzheimer's disease and dementia. Amnestix operates as a subsidiary of Sygnis Pharma AG and is dedicated to building a robust pipeline of cognitive enhancers to address the challenges posed by memory-related diseases.